Trials / Completed
CompletedNCT03614078
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- PRCL Research Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in moderate to severe chronic plaque psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRCL-02 | Oral tablets |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2018-09-25
- Primary completion
- 2019-04-29
- Completion
- 2019-07-08
- First posted
- 2018-08-03
- Last updated
- 2020-03-30
- Results posted
- 2020-03-30
Locations
16 sites across 3 countries: Canada, Slovakia, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03614078. Inclusion in this directory is not an endorsement.